Imjudo (Tremelimumab)
- Medicine Name: Imjudo
- Generic Name: Tremelimumab
- Dosage Form & Strength: Injection: 25 mg/1.25 mL (20 mg/mL), 300 mg/15 mL (20 mg/mL) solution in a single-dose vial
- Manufactured By: AstraZeneca Pharmaceuticals LP
Medical Uses
Imjudo is a CTLA-4 blocking antibody used:
In conjunction with Imfinzi (durvalumab) to treat adults with unresectable (cannot be removed by surgery) hepatocellular carcinoma (uHCC).
In conjunction with Imfinzi (durvalumab) and platinum-based chemotherapy to treat adults with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR-mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Recommended Dosage: Imjudo injection is given once, as a single infusion (drip) into a vein which lasts about 60 minutes. The first dose of Imfinzi (durvalumab) is given on the same day as the Imjudo. After that, it is given every 28 days on its own.
Recommended Dosage for uHCC:
Weight 30 kg and more: The recommended dosage of Imjudo is 300 mg as a single dose in conjunction with Imfinzi (durvalumab) 1,500 mg at Cycle 1 per Day 1, followed by Imfinzi (durvalumab) as a single agent every 28-days.
Weight less than 30 kg: The recommended dosage of Imjudo is 4 mg/kg as a single dose in conjunction with Imfinzi (durvalumab) 20 mg/kg at Cycle 1 per Day 1, followed by Imfinzi (durvalumab) as a single agent every 28-days.
Recommended dosage for Metastatic NSCLC:
Weight 30 kg and more: The recommended dosage of Imjudo is 75 mg every 21-days in conjunction with Imfinzi (durvalumab) 1,500 mg and platinum-based chemo for 4 cycles, and then administer drug Imfinzi (durvalumab) 1,500 mg every 28-days as a single agent with histology-based pemetrexed therapy every 28-days, and a 5th dose of Imjudo 75 mg in conjunction with Imfinzi (durvalumab) dose 6th at week 16.
Weight less than 30 kg: The recommended dosage is 1 mg per kg every 21-days together with Imfinzi (durvalumab) 20 mg per kg and platinum-based chemo for four cycles, and then administer Imfinzi 20 mg per kg every 28-days as a single agent with histology-based pemetrexed therapy every 28-days, and a 5th dose of Imjudo 1 mg/kg in conjunction with Imfinzi (durvalumab) dose 6th at week 16.
Warning & Precautions
- Imjudo 25 mg/1.25 mL together with Imfinzi can be responsible for causing immune-mediated hypophysitis. Hypophysitis can be responsible for causing hypopituitarism. Start symptomatic treatment including hormone replacement as clinically required.
- Assess patients for hyperglycemia or other manifestations of diabetes. start therapy with insulin as clinically needed. Withhold or permanently stop this treatment along with durvalumab based on the severity.
- Imjudo along with with durvalumab (Imfinzi) can be responsible for causing immune-mediated rash or dermatitis. Topical corticosteroids or topical emollients may be suitable for treating mild to moderate non-exfoliative rashes.
- Imjudo 300 mg/15 mL in conjunction with the drug Imfinzi can be responsible for causing severe or hazardous infusion-related reactions. Assess for the manifestation of infusion-related reactions. Interrupt, or slow the rate of, or permanently stop treatment and Imfinzi on behalf of the severity.
- Imjudo can be responsible for causing fetal harm if administered to a pregnant woman. Females of reproductive age should use relevant contraception during therapy with Imjudo injection and for 90 days after the last dose of Imjudo injection.
Documentation & Availability
What documents are required to import IMJUDO to India?
IMJUDO (tremelimumab-actl) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is IMJUDO available in India?
IMJUDO (tremelimumab-actl injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
IMJUDO can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Pune, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and certain other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of IMJUDO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).
Please contact +91-7575883015 | Number: +91-7575883015 or write us at sshealthcare1012@gmail.com for Imjudo injection price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the IMJUDO (Cancer Treatment Medicines) from across the globe and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Imjudo®?
Tremelimumab is a Generic Name for the trade name drug Imjudo®.
What is the Manufacturer’s Name of Imjudo®?
Imjudo® is manufactured by AstraZeneca Pharmaceuticals LP.
Is Imjudo® approved by the FDA?
Yes, Imjudo® is approved by the FDA. Date of first/initial approval: October 21, 2022.
Where can I get Imjudo® at the best price in India?
To get the best Imjudo price in India, kindly get in touch with S S Healthcare (a WHO GDP and ISO 9001:2008 certified company). For Imjudo®, a medical prescription is required from your treating physician.
What is the dosage and form of Imjudo® supplied?
Imjudo® is supplied as Injection: 300 mg/15 mL (20 mg/mL) and 25 mg/1.25 mL (20 mg/mL) solution in a single-dose vial for intravenous administration.
Where to Buy Imjudo® Injection in India?
Buy Imjudo 25 mg/1.25 mL and 300 mg/15 mL injection by AstraZeneca. Get quick delivery of medicines online from S S Healthcare at a reasonable price. S S Healthcare is a WHO GDP and ISO 9001 2015 certified Pharmaceutical Wholesaler/ Exporter/ Importer, and Imjudo Supplier from India.
What are the most common side effects of Imjudo®?
The most common side effects of Imjudo in patients with uHCC are diarrhea, rash, fatigue, abdominal pain, pruritus, and musculoskeletal pain.
The most common side effects of Imjudo in patients with metastatic NSCLC are fatigue, nausea, rash, musculoskeletal pain, decreased appetite, and diarrhea.
How much does Imjudo cost in India?
The cost of Imjudo in India can vary depending on international factors. To procure/source Imjudo legally, you can Call/WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Imjudo®?
Store in a refrigerator at temperatures 2 to 8°C (36 to 46°F) in the original carton in order to protect it from light. Neither freeze nor shake it.
Is it safe to buy Imjudo® online in India?
Yes, one can buy Imjudo in India at the best price from the S S Healthcare if Imjudo has not been launched or is unavailable in the country. We can help facilitate the Import of Imjudo through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
